EN

Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Campus life

Discover the campuses

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Join our programs

Shaker Gene.iO ATIGE

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Directories Our network

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Come to our events

Innovate with us

Discover >

Quick access

Company

Synsight

Pépinière Genopole Entreprises, 4 rue Pierre Fontaine
91058 EVRY – FRANCE
Phone: +33 1 69 47 01 76
Email: info@synsight.net

Cyril BAUVAIS: CEO
Site Web >
Synsight - Genopole's Company Synsight - Genopole's Company

#Therapeutics

  • Drug discovery
  • Chemoinformatics
  • Molecular modeling
  • High-content screening (HCS)
  • Artificial intelligence

Field of Activity

Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).

BACKGROUND
December 2013: Launch of SYNSIGHT
January 2018: Transition to a platform model for drug discovery
January 2019: Platform prototype ready to sell
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
SYNSIGHT’s platform encompasses artificial intelligence, molecular modeling and high-content screening to rationalize and accelerate the drug discovery projects of its partners.
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS

  • Collaboration with SABNP laboratory (Évry university and INSERM)
  • Successful consulting activity since 2013

COLLABORATIONS SOUGHT

SYNSIGHT’s business model involves developing R&D collaborations and licensing agreements with biotech and pharmaceutical companies.

SYNSIGHT takes charge of the discovery of new innovative drug candidates for novel therapeutic targets proposed by the partner.

  • Further Information

    6 staff members
    Annual Turnover: €100,000
    1 PATENT
    Strengths
    Collectively, the Synsight team has over 20 years of experience in chemoinformatics, molecular modeling, computational chemistry, structural biology, protein design and other related fields.
    Innovation Assets
    The Synsight platform offers the predictive capacity of artificial intelligence combined with the descriptive and explanatory capacity of molecular modeling furthermore enriched by quantitative and functional experimental data.

Share
Genopole’s Companies

#Therapeutics

In same field

Pharming - Genopole's company - Logo 2021

PHARMING

Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.

Discover
Genosafe - Genopole's Company

Genosafe

GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.

Discover
Généthon - Genopole's Laboratory

Généthon

Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.

Discover

Enterome

Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.

Discover
Logo Ab Science - Genopole's company

AB Science

Research, development and commercialization of tyrosine kinase inhibitors as targeted therapy for pathologies with unmet medical needs.

Discover
View all >
With the support from
Région île de France
Ministère de l'Enseignement supérieur et de la recherche AFM-Téléthon
Communauté d'agglomération Grand Paris Sud
Département de l'Essonne - Terre D'avenirs Ville d'Evry-Courcouronnes 2023 CEA Inserm Centre hospitalier Sud Francilien Université d'Evry - Paris Saclay Université PAris-Saclay SEM Genopole

Keep up to date with Genopole’s latest events and news